Literature DB >> 8052285

Donor T cells to treat EBV-associated lymphoma.

H E Heslop, M K Brenner, C M Rooney.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8052285     DOI： 10.1056/NEJM199409083311017

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  60 in total

Review 1.  Immunotherapy of melanoma.

Authors:  C Smith; V Cerundolo
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

2.  Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers.

Authors:  Kevin N Heller; Jenica Upshaw; Beza Seyoum; Henry Zebroski; Christian Münz
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

Review 3.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

4.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 5.  Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Authors:  Catherine M Bollard; Laurence J Cooper; Helen E Heslop
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 6.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

Review 7.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

9.  EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Authors:  C P Fox; D Burns; A N Parker; K S Peggs; C M Harvey; S Natarajan; D I Marks; B Jackson; G Chakupurakal; M Dennis; Z Lim; G Cook; B Carpenter; A R Pettitt; S Mathew; L Connelly-Smith; J A L Yin; M Viskaduraki; R Chakraverty; K Orchard; B E Shaw; J L Byrne; C Brookes; C F Craddock; S Chaganti
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

10.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.